JP2004529117A - 認知欠陥障害の処置における二重のｈ３／ｍ２アンタゴニストの使用 - Google Patents

認知欠陥障害の処置における二重のｈ３／ｍ２アンタゴニストの使用 Download PDF

Info

Publication number
JP2004529117A
JP2004529117A JP2002571052A JP2002571052A JP2004529117A JP 2004529117 A JP2004529117 A JP 2004529117A JP 2002571052 A JP2002571052 A JP 2002571052A JP 2002571052 A JP2002571052 A JP 2002571052A JP 2004529117 A JP2004529117 A JP 2004529117A
Authority
JP
Japan
Prior art keywords
antagonist
alkyl
group
histamine
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002571052A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004529117A5 (enExample
Inventor
ジョン エイ． ヘイ，
アスラニアン，　ロバート　ジー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2004529117A publication Critical patent/JP2004529117A/ja
Publication of JP2004529117A5 publication Critical patent/JP2004529117A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2002571052A 2001-02-08 2002-02-06 認知欠陥障害の処置における二重のｈ３／ｍ２アンタゴニストの使用 Pending JP2004529117A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26735201P 2001-02-08 2001-02-08
PCT/US2002/003975 WO2002072093A2 (en) 2001-02-08 2002-02-06 Use of dual h3/m2 antagonists with a bipiperidinic structure in the treatment of cognition deficit disorders

Publications (2)

Publication Number Publication Date
JP2004529117A true JP2004529117A (ja) 2004-09-24
JP2004529117A5 JP2004529117A5 (enExample) 2005-12-22

Family

ID=23018432

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002571052A Pending JP2004529117A (ja) 2001-02-08 2002-02-06 認知欠陥障害の処置における二重のｈ３／ｍ２アンタゴニストの使用

Country Status (6)

Country Link
US (1) US6906081B2 (enExample)
EP (1) EP1408965A2 (enExample)
JP (1) JP2004529117A (enExample)
AU (1) AU2002253929A1 (enExample)
CA (1) CA2436083A1 (enExample)
WO (1) WO2002072093A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004520435A (ja) * 2001-03-13 2004-07-08 シェーリング　コーポレイション 新規非イミダゾール化合物

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1777223A1 (en) * 2002-06-24 2007-04-25 Schering Corporation Indole derivatives useful as histamine H3 antagonists
US20050090527A1 (en) * 2003-01-28 2005-04-28 Schering Corporation Combination of H1, H3 and H4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
EP1646620B1 (en) * 2003-07-18 2007-08-15 Glaxo Group Limited Substituted piperidines as histamine h3 receptor ligands
GB0420831D0 (en) * 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
EP2813225B1 (en) * 2004-09-24 2017-12-13 University of Maryland, Baltimore Method of treating organophosphorous poisoning
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
US8541452B2 (en) * 2005-10-06 2013-09-24 Guy Chouinard Method for treating binge-eating disorder
US7728031B2 (en) 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
RU2486187C2 (ru) 2007-09-11 2013-06-27 Эбботт Лэборетриз N-ОКСИДЫ ОКТАГИДРО-ПИРРОЛО[3,4-b]ПИРРОЛА
MX344177B (es) * 2008-03-27 2016-12-08 Chase Pharmaceuticals Corp Uso y composicion para tratar la demencia.
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
HK1210947A1 (en) 2012-09-05 2016-05-13 Chase Pharmaceuticals Corporation Anticholinergic neuroprotective composition and methods
EP4251148A1 (en) * 2020-11-27 2023-10-04 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2624734A (en) * 1950-04-29 1953-01-06 Hoffmann La Roche Bipiperidine derivatives
GB8916947D0 (en) 1989-07-25 1989-09-13 Smith Kline French Lab Medicaments
GB9115740D0 (en) 1991-07-20 1991-09-04 Smithkline Beecham Plc Medicaments
ZA929788B (en) 1991-12-18 1993-06-22 Schering Corp Imidazolyl or imidazoylalkyl substituted with a four or five membered nitrogen containing heterocyclic ring.
US5633250A (en) 1991-12-18 1997-05-27 Schering Corporation Imidazoylalkyl substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
US5807872A (en) 1992-12-16 1998-09-15 Schering Corporation Imidazoylalkyl substituted with a six membered nitrogen containing heterocyclic ring
US5352707A (en) 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
US5446057A (en) 1993-09-24 1995-08-29 Warner-Lambert Company Substituted tetrahydropyridine and piperidine carboxylic acids as muscarinic antagonists
HUT74386A (en) 1993-11-15 1996-12-30 Schering Corp Phenyl-alkyl imidazoles as h3-receptor antagonists and pharmaceutical compositions containing them
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US5935958A (en) 1996-07-01 1999-08-10 Schering Corporation Muscarinic antagonists
US5952349A (en) 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
US5977138A (en) 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
US6034251A (en) 1997-11-07 2000-03-07 Schering Corporation Phenyl-alkyl-imidazoles
US5990147A (en) 1997-11-07 1999-11-23 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
US6066636A (en) 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
US6100279A (en) 1998-11-05 2000-08-08 Schering Corporation Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom
US6294554B1 (en) 1999-09-22 2001-09-25 Schering Corporation Muscarinic antagonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004520435A (ja) * 2001-03-13 2004-07-08 シェーリング　コーポレイション 新規非イミダゾール化合物

Also Published As

Publication number Publication date
EP1408965A2 (en) 2004-04-21
WO2002072093A2 (en) 2002-09-19
CA2436083A1 (en) 2002-09-19
US6906081B2 (en) 2005-06-14
WO2002072093A3 (en) 2004-01-22
US20020151565A1 (en) 2002-10-17
AU2002253929A1 (en) 2002-09-24

Similar Documents

Publication Publication Date Title
JP2004529117A (ja) 認知欠陥障害の処置における二重のｈ３／ｍ２アンタゴニストの使用
ES2927712T3 (es) Amidas deuteradas de piridona y profármacos de las mismas como moduladores de canales de sodio
EP4483882A2 (en) New methylquinazolinone derivatives
AU732096B2 (en) Ether muscarinic antagonists
HUP0103840A2 (hu) Új helyettesített piperidinszármazékok ORL-1 nociceptin receptorhoz, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
EP4346818B1 (en) Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
CZ223998A3 (cs) Derivát 5H-thiazolo/3,2-a/pyrimidinu, způsob jeho přípravy meziprodukt pro jeho přípravu a farmaceutický prostředek, který ho obsahuje
US6545028B2 (en) Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction
JP2002539208A (ja) Ｃｇｒｐアンタゴニストとしての修飾アミノ酸アミド
JP2023052462A (ja) ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物
US20110159096A1 (en) 1-(1H-1,2,4-Triazol-1-YL)Butan-2-OL Derivative For Pharmaceutical Use, and The Use Of a 1-(1H-1,2,4-Triazol-1-YL)Butan-2-OL Derivative With Substantially Undefined Crystal Shape For Preparing Said 1-(1H-1,2,4-Triazol-1-YL)Butan-2-OL Derivative
US7045522B2 (en) 8-Azabicyclo[3.2.1]oct-2-ene and -octane derivatives technical field
AU2007272720A1 (en) Methods for treating cystic kidney diseases
WO1997041108A1 (en) Substituted piperazines and piperidines as central nervous system agents
AU749094B2 (en) 1'-{4-{1- (4-fluorophenyl)- 1h-indole-3-yl} -1-butyl}-spiro {isobenzofuran- 1(3h),4'- piperidine} hydrohalogenides
RU2126404C1 (ru) 3r*, 4s* -3-[4-(4-фторфенил-4-гидроксипиперидин-1-ил] хроман- 4,7-диол, его оптические изомеры и фармацевтическая композиция на его основе и способы лечения
TW201118070A (en) Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity
JP2003532724A (ja) ソマトスタチン誘導体に親和性を有する、ヒダントイン誘導体
CA2466728C (en) Azetidinyl diamines useful as ligands of the nociceptin receptor orl-1
EP0885004B1 (en) Use of 4-phenyl-3,6-dihydro-2h-pyridyl derivatives as nmda receptor subtype blockers
WO1995003055A1 (en) At-2 antagonist inhibition of vascular restenosis
CN106243096A (zh) 三环类药物的新用途
US8772319B2 (en) Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process
EP1028947A1 (en) H3 receptor ligands of the phenyl-alkyl-imidazoles type
US20230357218A1 (en) N-formamidopyrazoline derivative as p2x3 receptor antagonist and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081117

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090409